Elsevier

The Journal of Hand Surgery

Volume 37, Issue 8, August 2012, Pages 1580-1584
The Journal of Hand Surgery

Scientific article
Clinical Outcomes of Total Wrist Arthroplasty

https://doi.org/10.1016/j.jhsa.2012.05.016Get rights and content

Purpose

Current indications for total wrist arthroplasty include patients with symptomatic end stage posttraumatic wrist arthritis, rheumatoid arthritis, and Kienböck disease, as an alternative to wrist arthrodesis. Arthroplasty may have advantage over arthrodesis because of the ability to retain motion. The purpose of this study was to evaluate the short-term clinical outcomes and complications of the Maestro Total Wrist System.

Methods

We report the results of a retrospective review of 23 total wrist prostheses implanted in 22 patients. We administered the visual analog pain scale and Mayo wrist and Disabilities of the Arm, Shoulder, and Hand questionnaires. We reviewed wrist motion, grip strength, radiographs, and complications.

Results

At a mean follow-up of 28 months (range, 4–55 mo), the Disabilities of the Arm, Shoulder, and Hand score and Mayo wrist score were 31 and 54, respectively. Mean pain scores improved from 8.0 to 2.2. The mean wrist flexion-extension arc was 90°. Radiographs revealed no evidence of prosthetic loosening. Grip strength averaged 60% of the strength of the opposite hand. Complications occurred in 7 of 23 patients. One failure occurred as a result of deep infection in a patient with prior intercarpal fusion, and was successfully converted to a wrist fusion.

Conclusions

Total wrist arthroplasty performed for pancarpal arthritis as an alternative to wrist arthrodesis can yield successful outcomes with low short-term failure rates.

Type of study/level of evidence

Therapeutic IV.

Section snippets

Materials and Methods

We obtained institutional review board authorization and performed a retrospective chart review on prospectively collected data for all patients who received a TWA from 2007 to 2011. Two fellowship-trained orthopedic hand surgeons at the same institution performed all procedures. The surgical indication for TWA was painful pancarpal arthritis in which wrist arthrodesis would be an alternative and in which proximal row carpectomy or 4-corner arthrodesis was not possible. If the radiolunate and

Results

At a mean follow-up of 28 months (range, 4–55 mo), we recorded range of motion, DASH, and Mayo wrist and visual analog pain scale scores (Table 1). Grip strength averaged 60% of the opposite hand. Table 2 lists the postoperative DASH and Mayo wrist scores, wrist range of motion, and visual analog pain scale scores separated by etiology. In addition, we obtained radiographs at each follow-up visit, which revealed no evidence of loosening or fractures.

The overall complication rate was 7 of 23

Discussion

Many reports exist regarding the efficacy of TWA. Cobb and Beckenbaugh13 reported on 52 cases using biaxial TWA. At 1 year after surgery, there was a statistical decrease in flexion and an increase in extension. Pain was reported as none in 75% of patients. Implant loosening was the most common complication (8 of 11 patients). The authors predicted that 1 in 5 implants would fail by 6 years.

Meuli and Fernandez14 presented their outcomes on 49 TWAs using the Meuli Wrist Prosthesis–third

Cited by (57)

  • Explant analysis of a Maestro™ wrist prosthesis and calculation of its lubrication regime

    2020, Journal of the Mechanical Behavior of Biomedical Materials
    Citation Excerpt :

    The functional range of motion of the natural wrist has been defined as 5° of flexion, 30° extension, 10° of radial deviation and 15° of ulnar deviation (Yeoh and Tourret, 2015). The Maestro™ wrist was found to be the only third-generation wrist that achieved this functional range of motion (Nydick et al., 2012) compared to other third-generation wrists such as the Universal, Universal 2, Biaxial, Remotion and Motec (Yeoh and Tourret, 2015). In addition, a 95% survivorship was recorded for the Maestro™ wrist at 8 years (Berber et al., 2018), whereas the mid-to long term survivorship of the Universal 2, Motec and the Remotion were 78%, 86% and 90% respectively (Schmidt, 2019).

View all citing articles on Scopus

A.V.H. receives royalties from, and has stock in, Upex and is a speaker for Biomet and Auxilium.

View full text